Clinical Trial

A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to observe the safety of IGT-303 in healthy volunteers and participants with Chronic Kidney Disease. The main question it aims to answer is: Is IGT-303 safe as a single dose or multiple dose regimen when applied under the skin (subcutaneously (SC)) or to a vein (intravenously (IV)). Researchers will compare IGT-303 against a placebo to see if IGT-303 is safe for use. Participants will be assigned to either IGT-303 or placebo and assessed for safety and tolerability for the duration of the study.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-11-14; most recent amendment 2026-05-14.
Status change: Not Yet Recruiting → Recruiting 2025-11-28
Trial Details
NCT Number NCT07231679
Lead Sponsor Ingenia Therapeutics INC
Conditions Healthy Volunteers, Chronic Kidney Disease
Enrollment 94 participants
Start Date 2025-10-30
Primary Completion 2026-10 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-18